Literature Review: Moving the Druggable Needle
The Use of an mRNA Display Technology and Affinity-Based Selection Is Used to Find Inhibitors to an Enzyme of Interest
To Surge or Not to Surge?
Experts Discuss Inclusion of a Surge Tank in an End-to-End Continuous Biomanufacturing Train
New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
For full access to this article login to GEN Select now.
Repligen Now a Bioprocess Product Firm
One-Time Therapeutics Player Bets Future on Working as Supplier to Bioprocess Companies
- Repligen, once a strongly focused therapeutics firm, has transformed itself into a bioprocess products company in only a few years’ time. As the company’s former COO Tony J. Hunt takes the helm as president and CEO after the May retirement of Walter C. Herlihy, Ph.D., that transformation will continue ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.